High-risk premenopausal women's experiences of undergoing prophylactic oophorectomy: A descriptive study

Genetic Testing

Volumn 8, Issue 2, 2004, Pages 148-156

  Hallowell, Nina ^a   Mackay, James ^b   Richards, Martin ^a   Gore, Martin ^c   Jacobs, Ian ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY IMAGE; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; EXPERIENCE; FEMALE; GENDER IDENTITY; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MEDICAL DECISION MAKING; OVARIECTOMY; OVARY CANCER; POSTOPERATIVE COMPLICATION; PREMENOPAUSE; PROPHYLAXIS; QUALITATIVE ANALYSIS; SUBSTITUTION THERAPY;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERVIEWS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT ACCEPTANCE OF HEALTH CARE; PREMENOPAUSE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 4143078046     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2004.8.148     Document Type: Article

References (24)

1. BABB, S.A., SWISHER, E.M., HOPE, N., et al. (2002). Qualitative evaluation of medical information processing needs of 60 women choosing ovarian cancer surveillance or prophylactic oophorectomy. J. Genet. Couns. 11, 81-96.
2. BURKE, W., DALY, M., GARBER, J., et al. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA1 and BRCA2. J. Am. Med. Assn. 277, 997-1003.
3. BRONNER, C.E., BAKER, S.M., MORRISON, P.T., et al. (1994). Mutation in the DNA mismatch repair gene homologue hMLH1 is associate with hereditary non-polyposis colon cancer. Nature 368, 258-261.
4. EASTON, D.F., FORD, D., BISHOP, D.T., and THE BREAST CANCER LINKAGE CONSORTIUM. (1995). Breast and ovarian cancer incidence in BRCA1 mutation carriers, Am. J. Hum. Genet. 56, 265-271.
5. EISINGER, F., ALBY, N., DAUPLAT, J., et al. (1998). Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. Ann. Oncol. 9, 939-950.
6. FORD, D., EASTON, D.F., STRATTON, M., et al., and THE BREAST CANCER LINKAGE CONSORTIUM. (1997). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 62, 676-689.
7. FRY, A., RUSH, R., and BUSBY-EARLE, C. (2001a). Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer? Prev. Med. 33, 578-585.
8. FRY, A., BUSBY-EARLE, C., and RUSH, R. (2001b). Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 10, 231-241.
9. HALLOWELL, N. (2000). A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psycho-Oncology 9, 486-495.
10. HALLOWELL, N., and LAWTON, J. (2002). Negotiating present and future selves: decision-making about prophylactic surgery for hereditary ovarian cancer. Health 6, 423-443.
11. HALLOWELL, N., JACOBS, I., RICHARDS, M.P.M., et al. (2001). Surveillance or surgery? A description of the factors that influence high-risk premenopausal women's decisions about prophylactic oophorectomy J. Med. Genet. 38, 683-691.
12. LEACH, F.S., NICOLAIDES, N.C., PAPADOPOULOS, N., et al. (1993). Mutations of a MutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75, 1215-1225.
13. MEISER, B., BUTOW, P., BARRATT, A., et al. (1999). Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol. Oncol. 75, 122-129.
14. MEISER, B., TILLER, K., GLEESON, M.A., et al. (2000). Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 9, 496-503.
15. MIKI, J., SWENSEN, J., SHATTUCK-EIDENS, D., et al. (1994). A strong candidate for the breast ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
16. MILLER, S.M., FANG, C.Y., MANNE, S.L., et al. (1999). Decision-making about prophylactic oophorectomy among at-risk women: psychological influences and implications. Gynecol Oncol 75, 406-412.
17. MUHR, T. (1994). Atlas-ti: Computer aided text interpretation and theory building. Muhr, Berlin.
18. National Institutes of Health. (1994). Consensus Conference Statement Ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55, S4-S14.
19. REBBECK, T.R., LYNCH, H.T., NEUHAUSEN, S.L., et al. and THE PREVENTION AND OBSERVATION OF SURGICAL END POINTS STUDY GROUP. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations: N. Engl. J. Med. 346, 1616-1622.
20. STRAUSS, A., and CORBIN, J. (1990). Basics of qualitative research. Sage, London.
21. SWISHER, E.M., BABB, S., WHELAN, A., et al. (2001). Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction J. Reprod. Med. 46, 87-94.
22. WHITTEMORE, A.S., GONG, G., and ITNYRE, J. (1998). Prevalence and contribution of BRCA1 mutations in breast and ovarian cancer: results from three U.S. Population-based case-control studies of ovarian cancer. Am. J. Hum. Genet. 60, 496-504.
23. WOMEN'S HEALTH INITIATIVE. (2002). Risks and benefits of Estrogen plus Progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. J. Am. Med. Assn. 288, 321-333.
24. WOOSTER, R., BIGNELL, G., LANCASTER, J., et al. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-791.